{"id":52872,"date":"2023-01-12T19:02:14","date_gmt":"2023-01-12T18:02:14","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/the-views-of-103-italian-patient-groups-on-the-corporate-reputation-of-pharma-2021-2022-researchandmarkets-com\/"},"modified":"2023-01-12T19:02:14","modified_gmt":"2023-01-12T18:02:14","slug":"the-views-of-103-italian-patient-groups-on-the-corporate-reputation-of-pharma-2021-2022-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/the-views-of-103-italian-patient-groups-on-the-corporate-reputation-of-pharma-2021-2022-researchandmarkets-com\/","title":{"rendered":"The Views of 103 Italian Patient Groups on the Corporate Reputation of Pharma, 2021-2022 &#8211; ResearchAndMarkets.com"},"content":{"rendered":"<div>\n<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5455969\/the-corporate-reputation-of-pharma-in-2021-the?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=fkdqh3&amp;utm_campaign=1807182+-+The+Views+of+103+Italian+Patient+Groups+on+the+Corporate+Reputation+of+Pharma%2C+2021-2022&amp;utm_exec=chdo54prd\" rel=\"nofollow noopener\" shape=\"rect\">&#8220;The Corporate Reputation of Pharma in 2021 &#8211; The Patient Perspective &#8211; Italy Edition: The Views of 103 Italian Patient Groups&#8221;<\/a> report has been added to <strong>ResearchAndMarkets.com&#8217;s<\/strong> offering.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230112005734\/en\/1684869\/4\/logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230112005734\/en\/1684869\/21\/logo.jpg\"><\/a><\/p>\n<p>\nThe &#8216;Corporate Reputation of Pharma&#8217; survey &#8211; the 2021 Italy edition is now in its 8th year, and two years into the Covid-19 pandemic. Between November 2021-February 2022, the survey collected the opinions of 103 Italy-based patient groups on the performance of the pharmaceutical industry during 2021.\n<\/p>\n<p>\nPatient groups possess a unique understanding of the needs of the patients and represent their collated views. Patient-group perspectives have become increasingly important to regulators that demand patient input into trial design and conduct, as well as into the evaluation of clinical outcomes. At the same time, many patient groups are also familiar with the complexities of pharma&#8217;s business. From their vantage point, therefore, patient groups are both able to assess pharma, and recommend ways in which companies can improve &#8211; all from a patient perspective.\n<\/p>\n<p>\n2021&#8217;s 103 respondent Italian patient groups had, collectively, been in communication with 959,000 Italian patients during the year. 76% of the Italian patient groups responding to the 2021 &#8216;Corporate Reputation of Pharma&#8217; survey worked or partnered with at least one pharma company that year.\n<\/p>\n<p>\n<strong>The report provides details on:<\/strong>\n<\/p>\n<ul>\n<li>\nHow the analyst measures pharma&#8217;s corporate reputation from a patient perspective;\n<\/li>\n<li>\nThe headline results of the 2021 Italy element of the &#8216;Corporate Reputation&#8217; survey;\n<\/li>\n<li>\nThe companies included in the 2021 Italy analysis; and\n<\/li>\n<li>\nThe profiles of 2021&#8217;s respondent Italian patient groups.\n<\/li>\n<\/ul>\n<p>\n<strong>Company Rankings<\/strong>\n<\/p>\n<ul>\n<li>\nThe top-three pharma companies in Italy in 2021, out of 22 companies, ranked for their overall corporate reputation (as assessed by respondent Italian patient groups familiar with the company): Roche, 1st &#8211; Novo Nordisk, 2nd &#8211; Pfizer, 3rd.\n<\/li>\n<li>\nThe top-three pharma companies in Italy in 2021, out of 6 companies, ranked for their overall corporate reputation (as assessed by respondent Italian patient groups working with the company): Pfizer, 1st &#8211; Roche, 2nd &#8211; Novartis, 3rd.\n<\/li>\n<li>\nThe top-three &#8216;big-pharma&#8217; companies in Italy in 2021, out of 12 &#8216;big-pharma&#8217; companies, ranked for their overall corporate reputation (as assessed by respondent Italian patient groups familiar with the company): Roche, 1st &#8211; Pfizer, 2nd &#8211; GSK, 3rd.\n<\/li>\n<li>\nThe top-three &#8216;big-pharma&#8217; companies in Italy in 2021, out of 5 &#8216;big-pharma&#8217; companies, ranked for their overall corporate reputation (as assessed by respondent Italian patient groups working with the company): Pfizer, 1st &#8211; Roche, 2nd &#8211; Novartis, 3rd.\n<\/li>\n<\/ul>\n<p>\n<strong>Key Topics Covered:<\/strong>\n<\/p>\n<ol>\n<li>\nExecutive summary\n<\/li>\n<li>\nItalian patient-group relationships with pharma\n<\/li>\n<li>\nIndustry-wide findings\n<\/li>\n<li>\nThe corporate-reputation rankings of 25 pharma companies, 2020 (v. 2019), as assessed by Italian patient groups familiar with the companies\n<\/li>\n<li>\nThe corporate-reputation rankings of 5 pharma companies, 2020, as assessed by Italian patient groups that work\/partner with the companies\n<\/li>\n<li>\nProfiles of the 25 companies, 2020 (v. 2019)\n<\/li>\n<\/ol>\n<p>\n<strong>APPENDICES<\/strong>\n<\/p>\n<p>\nI Profiles of respondent Italian patient groups, 2020\n<\/p>\n<p>\nII List of respondent Italian patient groups that wished to be attributed, 2020\n<\/p>\n<p>\nIII What respondent Italian patient groups say about pharma (and how the industry can improve), 2020\/2021\n<\/p>\n<p>\n<strong>Companies Mentioned<\/strong>\n<\/p>\n<ul>\n<li>\nAbbVie\n<\/li>\n<li>\nAstraZeneca\n<\/li>\n<li>\nBayer\n<\/li>\n<li>\nBiogen\n<\/li>\n<li>\nBoehringer\n<\/li>\n<li>\nIngelheim\n<\/li>\n<li>\nBristol Myers Squibb\n<\/li>\n<li>\nChiesi Farmaceutici\n<\/li>\n<li>\nEli Lilly\n<\/li>\n<li>\nGilead Sciences\n<\/li>\n<li>\nGSK\n<\/li>\n<li>\nJanssen\n<\/li>\n<li>\nMenarini\n<\/li>\n<li>\nMSD\n<\/li>\n<li>\nMylan\n<\/li>\n<li>\nNovartis\n<\/li>\n<li>\nNovo Nordisk\n<\/li>\n<li>\nPfizer\n<\/li>\n<li>\nRoche\n<\/li>\n<li>\nSandoz\n<\/li>\n<li>\nSanofi\n<\/li>\n<li>\nTakeda\n<\/li>\n<li>\nTeva\n<\/li>\n<\/ul>\n<p>\nFor more information about this report visit <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5455969\/the-corporate-reputation-of-pharma-in-2021-the?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=fkdqh3&amp;utm_campaign=1807182+-+The+Views+of+103+Italian+Patient+Groups+on+the+Corporate+Reputation+of+Pharma%2C+2021-2022&amp;utm_exec=chdo54prd\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.researchandmarkets.com\/r\/90okm2<\/a>\n<\/p>\n<p>\n<strong>About ResearchAndMarkets.com<\/strong>\n<\/p>\n<p>\nResearchAndMarkets.com is the world&#8217;s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nResearchAndMarkets.com<br \/>\n<br \/>Laura Wood, Senior Press Manager<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#108;&#116;o:&#x70;&#x72;&#x65;&#x73;&#115;&#64;re&#x73;&#x65;&#x61;&#114;&#99;&#104;an&#x64;&#x6d;&#x61;&#114;&#107;et&#x73;&#x2e;&#x63;&#x6f;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#112;&#x72;e&#115;&#x73;&#64;&#x72;e&#115;&#x65;a&#x72;&#x63;&#104;&#x61;n&#100;&#x6d;a&#x72;&#x6b;&#101;&#x74;s&#46;&#x63;&#111;&#x6d;<\/a><\/p>\n<p>For E.S.T Office Hours Call 1-917-300-0470<br \/>\n<br \/>For U.S.\/ CAN Toll Free Call 1-800-526-8630<br \/>\n<br \/>For GMT Office Hours Call +353-1-416-8900\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;The Corporate Reputation of Pharma in 2021 &#8211; The Patient Perspective &#8211; Italy Edition: The Views of 103 Italian Patient Groups&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. The &#8216;Corporate Reputation of Pharma&#8217; survey &#8211; the 2021 Italy edition is now in its 8th year, and two years into the Covid-19 pandemic. Between &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/the-views-of-103-italian-patient-groups-on-the-corporate-reputation-of-pharma-2021-2022-researchandmarkets-com\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-52872","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>The Views of 103 Italian Patient Groups on the Corporate Reputation of Pharma, 2021-2022 - ResearchAndMarkets.com - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/the-views-of-103-italian-patient-groups-on-the-corporate-reputation-of-pharma-2021-2022-researchandmarkets-com\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Views of 103 Italian Patient Groups on the Corporate Reputation of Pharma, 2021-2022 - ResearchAndMarkets.com - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;The Corporate Reputation of Pharma in 2021 &#8211; The Patient Perspective &#8211; Italy Edition: The Views of 103 Italian Patient Groups&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. The &#8216;Corporate Reputation of Pharma&#8217; survey &#8211; the 2021 Italy edition is now in its 8th year, and two years into the Covid-19 pandemic. Between ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/the-views-of-103-italian-patient-groups-on-the-corporate-reputation-of-pharma-2021-2022-researchandmarkets-com\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-12T18:02:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230112005734\/en\/1684869\/21\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-views-of-103-italian-patient-groups-on-the-corporate-reputation-of-pharma-2021-2022-researchandmarkets-com\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-views-of-103-italian-patient-groups-on-the-corporate-reputation-of-pharma-2021-2022-researchandmarkets-com\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"The Views of 103 Italian Patient Groups on the Corporate Reputation of Pharma, 2021-2022 &#8211; ResearchAndMarkets.com\",\"datePublished\":\"2023-01-12T18:02:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-views-of-103-italian-patient-groups-on-the-corporate-reputation-of-pharma-2021-2022-researchandmarkets-com\\\/\"},\"wordCount\":620,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-views-of-103-italian-patient-groups-on-the-corporate-reputation-of-pharma-2021-2022-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230112005734\\\/en\\\/1684869\\\/21\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-views-of-103-italian-patient-groups-on-the-corporate-reputation-of-pharma-2021-2022-researchandmarkets-com\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-views-of-103-italian-patient-groups-on-the-corporate-reputation-of-pharma-2021-2022-researchandmarkets-com\\\/\",\"name\":\"The Views of 103 Italian Patient Groups on the Corporate Reputation of Pharma, 2021-2022 - ResearchAndMarkets.com - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-views-of-103-italian-patient-groups-on-the-corporate-reputation-of-pharma-2021-2022-researchandmarkets-com\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-views-of-103-italian-patient-groups-on-the-corporate-reputation-of-pharma-2021-2022-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230112005734\\\/en\\\/1684869\\\/21\\\/logo.jpg\",\"datePublished\":\"2023-01-12T18:02:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-views-of-103-italian-patient-groups-on-the-corporate-reputation-of-pharma-2021-2022-researchandmarkets-com\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-views-of-103-italian-patient-groups-on-the-corporate-reputation-of-pharma-2021-2022-researchandmarkets-com\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-views-of-103-italian-patient-groups-on-the-corporate-reputation-of-pharma-2021-2022-researchandmarkets-com\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230112005734\\\/en\\\/1684869\\\/21\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230112005734\\\/en\\\/1684869\\\/21\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-views-of-103-italian-patient-groups-on-the-corporate-reputation-of-pharma-2021-2022-researchandmarkets-com\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The Views of 103 Italian Patient Groups on the Corporate Reputation of Pharma, 2021-2022 &#8211; ResearchAndMarkets.com\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The Views of 103 Italian Patient Groups on the Corporate Reputation of Pharma, 2021-2022 - ResearchAndMarkets.com - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/the-views-of-103-italian-patient-groups-on-the-corporate-reputation-of-pharma-2021-2022-researchandmarkets-com\/","og_locale":"en_US","og_type":"article","og_title":"The Views of 103 Italian Patient Groups on the Corporate Reputation of Pharma, 2021-2022 - ResearchAndMarkets.com - Pharma Trend","og_description":"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;The Corporate Reputation of Pharma in 2021 &#8211; The Patient Perspective &#8211; Italy Edition: The Views of 103 Italian Patient Groups&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. The &#8216;Corporate Reputation of Pharma&#8217; survey &#8211; the 2021 Italy edition is now in its 8th year, and two years into the Covid-19 pandemic. Between ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/the-views-of-103-italian-patient-groups-on-the-corporate-reputation-of-pharma-2021-2022-researchandmarkets-com\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-12T18:02:14+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230112005734\/en\/1684869\/21\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/the-views-of-103-italian-patient-groups-on-the-corporate-reputation-of-pharma-2021-2022-researchandmarkets-com\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/the-views-of-103-italian-patient-groups-on-the-corporate-reputation-of-pharma-2021-2022-researchandmarkets-com\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"The Views of 103 Italian Patient Groups on the Corporate Reputation of Pharma, 2021-2022 &#8211; ResearchAndMarkets.com","datePublished":"2023-01-12T18:02:14+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/the-views-of-103-italian-patient-groups-on-the-corporate-reputation-of-pharma-2021-2022-researchandmarkets-com\/"},"wordCount":620,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/the-views-of-103-italian-patient-groups-on-the-corporate-reputation-of-pharma-2021-2022-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230112005734\/en\/1684869\/21\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/the-views-of-103-italian-patient-groups-on-the-corporate-reputation-of-pharma-2021-2022-researchandmarkets-com\/","url":"https:\/\/pharma-trend.com\/en\/the-views-of-103-italian-patient-groups-on-the-corporate-reputation-of-pharma-2021-2022-researchandmarkets-com\/","name":"The Views of 103 Italian Patient Groups on the Corporate Reputation of Pharma, 2021-2022 - ResearchAndMarkets.com - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/the-views-of-103-italian-patient-groups-on-the-corporate-reputation-of-pharma-2021-2022-researchandmarkets-com\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/the-views-of-103-italian-patient-groups-on-the-corporate-reputation-of-pharma-2021-2022-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230112005734\/en\/1684869\/21\/logo.jpg","datePublished":"2023-01-12T18:02:14+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/the-views-of-103-italian-patient-groups-on-the-corporate-reputation-of-pharma-2021-2022-researchandmarkets-com\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/the-views-of-103-italian-patient-groups-on-the-corporate-reputation-of-pharma-2021-2022-researchandmarkets-com\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/the-views-of-103-italian-patient-groups-on-the-corporate-reputation-of-pharma-2021-2022-researchandmarkets-com\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230112005734\/en\/1684869\/21\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230112005734\/en\/1684869\/21\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/the-views-of-103-italian-patient-groups-on-the-corporate-reputation-of-pharma-2021-2022-researchandmarkets-com\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"The Views of 103 Italian Patient Groups on the Corporate Reputation of Pharma, 2021-2022 &#8211; ResearchAndMarkets.com"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52872","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=52872"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52872\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=52872"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=52872"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=52872"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}